Daniel P. Petrylak, MD, presented “Sacituzumab Govitecan Given Accelerated FDA Approval for Advanced Urothelial Cancer” for the Grand Rounds in Urology audience in April 2021.
How to cite: Petrylak, Daniel P. “Sacituzumab Govitecan Given Accelerated FDA Approval for Advanced Urothelial Cancer” April 2021. Accessed Dec 2024. https://grandroundsinurology.com/sacituzumab-govitecan-given-accelerated-fda-approval-for-advanced-urothelial-cancer/
Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, discusses the FDA’s recent approval of sacituzumab govitecan for metastatic urothelial carcinoma. He notes how previously, treatment options were limited for patients who failed initial chemotherapy. Dr. Petrylak then describes how this new antibody drug conjugate acts as a “smart bomb” in the way it can recognize cancer markers and deliver chemotherapy directly to affected cells. He describes the trial that led to the approval of sacituzumab govitecan, including differences between it and enfortumab vedotin, how treatment has been combined with both drugs, and how it is expanding the spectrum of treatments for advanced urothelial carcinoma. Dr. Petrylak also discusses side effects of the drug and potential next steps for its use in treatment.
For more from Dr. Petrylak on clinical trials in this area, view his discussion on enfortumab vedotin from last year.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
